{"id":5897,"date":"2017-02-17T09:20:53","date_gmt":"2017-02-17T14:20:53","guid":{"rendered":"https:\/\/medicarereport.org\/?p=5897"},"modified":"2017-02-17T09:20:53","modified_gmt":"2017-02-17T14:20:53","slug":"exclusive-crispr-licenses-slow-development-of-therapies-legal-experts-argue","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=5897","title":{"rendered":"Exclusive CRISPR licenses slow development of therapies, legal experts argue"},"content":{"rendered":"<p>(By Sharon Begley for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">T<\/span>he exclusive licenses granted to three\u00a0for-profit companies on key discoveries about the revolutionary genome-editing technology CRISPR-Cas9 threaten to \u201cbottleneck\u201d its use \u201cto discover and develop useful human therapeutics,\u201d patent experts argued in a paper published on Thursday. <a href=\"https:\/\/www.statnews.com\/2017\/02\/16\/crispr-exclusive-licenses\/\" target=\"_blank\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"stat-logo\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Sharon Begley for STAT) The exclusive licenses granted to three\u00a0for-profit companies on key discoveries about the revolutionary genome-editing technology<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19,14],"tags":[],"class_list":["post-5897","post","type-post","status-publish","format-standard","hentry","category-legal-actionscourt-decisions","category-medical-technology"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5897"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5897\/revisions"}],"predecessor-version":[{"id":5898,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5897\/revisions\/5898"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}